In addition, GM2A levels are elevated in AD brain tissue in our cohort and are elevated in AD cerebrospinal fluid (CSF) in a cohort of 384 individuals (202 control vs. 182 AD). This evidence concerns the gene GM2A and Alzheimer disease.